Webinar | The PHOENIx MDR-TB Trial | Thursday, January 19th at 08:30 EST (13:30 CET, 14:30 SAST)

Mark your calendar for Thursday, January 19th from 08:30 to 09:30 EST (13:30-14:30 CET, 14:30-15:30 SAST) for a presentation from Dr. Gavin Churchyard, MBBCh, MMED, FCP (SA), PhD, entitled “Protecting MDR-TB and XDR-TB Affected Households: The PHOENIx MDR-TB Trial”.
The Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx) Study, is a phase III trial in development by the ACTG and IMPAACT networks aiming to asses the efficacy of six months of daily delamanid versus six months of isoniazid preventive therapy in high-risk household contacts of adult pulmonary MDR-TB cases.

Connection details forthcoming.